药物性肾损害 中国就医指南

Drug-induced nephrotoxicity refers to acute or chronic kidney injury caused by exposure to pharmacologic agents—either therapeutic doses of commonly prescribed medications or overdose/abuse scenarios. It is a leading cause of hospital-acquired acute kidney injury (AKI), accounting for approximately 19–25% of all AKI cases in inpatient settings globally. Pathophysiologically, nephrotoxicity arises through multiple mechanisms: direct tubular epithelial cell injury (e.g., aminoglycosides, cisplatin), intrarenal vasoconstriction and ischemia (e.g., NSAIDs, calcineurin inhibitors), crystal-induced tubular obstruction (e.g., acyclovir, sulfonamides, methotrexate), immune-mediated interstitial nephritis (e.g., PPIs, beta-lactams, diuretics), or glomerular damage (e.g., pamidronate, ifosfamide). Risk factors are multifactorial and include advanced age (>65 years), preexisting chronic kidney disease (CKD), diabetes mellitus, hypertension, heart failure, volume depletion, concurrent use of multiple nephrotoxic agents (e.g., dual RAAS blockade + NSAID), and genetic polymorphisms affecting drug metabolism (e.g., GSTM1 null genotype increasing cisplatin toxicity). Epidemiologically, incidence varies widely by clinical setting: among hospitalized adults, it affects 3–10% of patients receiving high-risk drugs; in oncology units, up to 30% of patients receiving platinum-based chemotherapy develop some degree of renal impairment. Critically, early recognition remains challenging due to nonspecific symptoms—including fatigue, nausea, decreased urine output, peripheral edema, and confusion—which often overlap with underlying illness or comorbidities. Untreated or severe cases may progress to dialysis-dependent kidney failure, prolonged hospitalization, or increased 90-day mortality (up to 25% in ICU-associated nephrotoxic AKI). Quality of life is significantly compromised: patients report persistent fatigue, cognitive slowing, sleep disturbances, anxiety about long-term kidney health, and limitations in physical activity and employment. Those requiring dialysis face substantial psychosocial burden, dietary restrictions, frequent clinic visits, and reduced health-related quality of life scores (measured by KDQOL-SF) comparable to end-stage heart failure. Importantly, many cases are preventable through vigilant medication review, dose adjustment per eGFR, hydration optimization, avoidance of drug combinations with synergistic toxicity, and real-time monitoring of serum creatinine and urinary biomarkers (e.g., NGAL, KIM-1) in high-risk populations.

# 药物性肾损害治疗方案与费用明细（肾内科）

一、非手术/保守治疗方案

适用人群：急性肾损伤早期（Scr↑＜50%）、eGFR＞30 mL/min/1.73m²、无少尿/高钾/心衰等危象者。

• •基础干预：停用可疑药物+水化+碱化尿液（碳酸氢钠）——0元（医保全额报销）
• •药物治疗（分档）：

- 进阶档（静脉甲泼尼龙冲击+免疫抑制剂）：甲强龙500 mg×3d +他克莫司，药费：2,800–6,500元/疗程

• •检验检查费：血肌酐、尿NAG酶、β2-MG、肾脏超声、24h尿蛋白定量——合计：420–680元

二、介入/核心治疗方案

适用条件：重症急性间质性肾炎伴肾功能急剧恶化（Scr↑＞100%）、病理证实肉芽肿或纤维素样坏死。

• •肾穿刺活检（核心诊断手段）：超声引导下经皮穿刺，含病理光镜+免疫荧光+电镜——总费用：3,200–4,900元（含术前凝血、B超定位、术后监护）
• •血液净化支持（CRRT）：用于合并高钾、肺水肿或尿毒症症状者，单次治疗——4,500–6,800元/天

三、特殊复杂/晚期方案

• •难治性间质纤维化+CKD 4–5期：长期RAS抑制剂+SGLT2i+营养支持，年均药费12,000–22,000元；进入透析阶段后，HD年均自付约18,000–35,000元（含医保后）
• •药物相关ANCA血管炎继发肾损害：利妥昔单抗诱导治疗——单次输注：12,000–18,000元

四、方案快速选择指南

• •预算有限/初发轻症：选保守治疗+基础药物，总费用＜1,500元（含检查）
• •中重度但可逆：肾穿刺+激素冲击，总费用约8,000–12,000元
• •晚期/并发症多：转入慢病管理或替代治疗，需专科长期随访与个体化方案